Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scienture Holdings, Inc.

1.58
-0.8300-34.44%
Post-market: 1.55-0.0300-1.90%19:59 EST
Volume:1.59M
Turnover:2.85M
Market Cap:14.21M
PE:0.44
High:2.15
Open:2.09
Low:1.51
Close:2.41
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-CoreCivic, Teladoc, Dynavax

Reuters
·
06 Mar

Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US

MT Newswires Live
·
06 Mar

Scienture Holdings Shares up 45.7% on Launch of Opioid Overdose Antidote Rezenopy

THOMSON REUTERS
·
06 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Scienture, ARS Pharma, BrightSpring Health

Reuters
·
06 Mar

BRIEF-Scienture To Commercially Launch Rezenopy

Reuters
·
06 Mar

BUZZ-Scienture Holdings rises on launch of opioid overdose antidote Rezenopy

Reuters
·
06 Mar

Scienture to commercially launch REZENOPY through Kindeva collaboration

TIPRANKS
·
06 Mar

Scienture to Commercially Launch Rezenopy®, a Life-Saving Opioid Overdose Emergency Treatment Through a Collaboration With Kindeva Drug Delivery L.p.

THOMSON REUTERS
·
06 Mar

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

GlobeNewswire
·
06 Mar

Scienture Holdings, Inc. Announces DR. Narasimhan Mani’s Participation in the 8TH Annual Conference of the Society for the Study of Xenobiotics

THOMSON REUTERS
·
21 Jan

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

GlobeNewswire
·
21 Jan

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

GlobeNewswire
·
17 Dec 2024

Scienture, Llc, a Wholly Owned Subsidiary of Scienture Holdings, Inc. (Nasdaq: Scnx) Announces Issuance of a New Patent Covering Its First Product Scn-102 (Losartan Potassium Oral Suspension, 10Mg/Ml) Through 2041

THOMSON REUTERS
·
10 Dec 2024

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

GlobeNewswire
·
10 Dec 2024

BRIEF-Scienture Holdings Files For Resale Of Up To 4.3 Mln Shares Of Common Stock

Reuters
·
05 Dec 2024

Scienture Files for Shareholders to Sell Up to 4.3 Million Common Shares

MT Newswires Live
·
05 Dec 2024